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Retinoic acid receptor α as a novel 
contributor to adrenal cortex 
structure and function through 
interactions with Wnt and Vegfa 
signalling
Rami M. el Zein  1,2, Audrey H. Soria  1,2, Jose Felipe Golib Dzib3, Amanda J. Rickard1,2, 
fabio L. fernandes-Rosa1,2, Benoit Samson-couterie1,2, Isabelle Giscos-Douriez1,2, 
Angélique Rocha1,2, Marko poglitsch4, Celso E. Gomez-Sanchez5, Laurence Amar1,2,6, 
Norbert B. Ghyselinck7,8,9, Arndt Benecke  3,10, Maria-Christina Zennaro1,2,11 & 
Sheerazed Boulkroun  1,2
Primary aldosteronism (PA) is the most frequent form of secondary arterial hypertension. Mutations 
in different genes increase aldosterone production in PA, but additional mechanisms may contribute 
to increased cell proliferation and aldosterone producing adenoma (APA) development. We performed 
transcriptome analysis in APA and identified retinoic acid receptor alpha (RARα) signaling as a central 
molecular network involved in nodule formation. To understand how RARα modulates adrenal 
structure and function, we explored the adrenal phenotype of male and female Rarα knockout mice. 
inactivation of Rarα in mice led to significant structural disorganization of the adrenal cortex in both 
sexes, with increased adrenal cortex size in female mice and increased cell proliferation in males. 
Abnormalities of vessel architecture and extracellular matrix were due to decreased Vegfa expression 
and modifications in extracellular matrix components. On the molecular level, Rarα inactivation leads 
to inhibition of non-canonical Wnt signaling, without affecting the canonical Wnt pathway nor PKA 
signaling. Our study suggests that Rarα contributes to the maintenance of normal adrenal cortex 
structure and cell proliferation, by modulating Wnt signaling. Dysregulation of this interaction may 
contribute to abnormal cell proliferation, creating a propitious environment for the emergence of 
specific driver mutations in PA.
Primary aldosteronism (PA) is the most common and curable form of secondary arterial hypertension, with preva-
lence estimations of up to 10% of cases in referred hypertensive patients, 4% of patients in primary care1,2 and 20% 
of patients with resistant hypertension3,4. Rapid diagnosis and treatment are important to prevent severe cardiovas-
cular consequences of long term aldosterone exposure, which are independent of blood pressure levels and are due 
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Figure 1. Transcriptome analysis reveals two distinct subgroups of APA. (A) Hierarchical clustering using 
Euclidean distance and complete linkage of 48 APA and 11 control adrenals. Heat-map of the whole gene 
expression is displayed using black for low expression and green for high expression. (B) Principal Component 
Analysis in the correlation space over the entire transcriptome. The first two principal components and their 
associated inertia are displayed. (C) Singular-value-decomposition-initialized multidimensional scaling 
under the correlation space over all genes86,87. Kruskal error is indicated as “stress”. (D) Aldosterone synthase 
immunohistochemistry performed on adrenals from APA_A and APA_B. (E) Three groups (APA_A, APA_B 
and CA) are pair-wise compared to obtain a list of statistically significantly expressed candidate genes for each 
of the three comparisons. The common and comparison-specific genes are classified in seven different groups 
some of which are associated to a biological process. Venn-diagrams are displayed for statistically significantly 
differentially expressed candidate genes. The smaller Venn diagrams on the right-hand side of the figure 
represent the overlap for up-regulated and down-regulated genes. Bars are displayed next to the represented 
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to deleterious cardiovascular effects of the hormone5,6. Indeed, patients with PA have an increased risk of developing 
stroke, coronary artery disease, atrial fibrillation, left ventricular hypertrophy, and heart failure2,5,7–9. In the majority 
of cases, PA is due to an aldosterone producing adenoma (APA) or bilateral adrenal hyperplasia (BAH)10. Patients 
with PA present hypertension, a high aldosterone to renin ratio and variable hypokalemia11. Over recent years, 
whole exome sequencing (WES) unraveled different somatic mutations in genes encoding ion channels (KCNJ5 and 
CACNA1D) and ATPases (ATP1A1 and ATP2B3)12–15 in about 50% of APA16. Recently, use of aldosterone synthase 
immunohistochemistry-guided next-generation sequencing identified somatic mutations in up to 88% of APA17. 
In physiological conditions, these channels and pumps play an important role in regulating intracellular ion home-
ostasis as well as maintaining cell membrane potential. When mutated, they induce cell membrane depolarization 
leading to opening of voltage-gated calcium channels, or directly affect intracellular calcium concentrations. This 
ultimately leads to activation of calcium signaling, the main trigger of aldosterone production. Although the link 
between mutations and aldosterone production has been clearly established, their role in promoting abnormal cell 
proliferation and/or APA development is not well understood. Activating mutations in the CTNNB1 gene (encod-
ing β-catenin) were also identified in 2–5% of APA18,19, and the Wnt/β-catenin signaling pathway has been shown 
to be constitutively active in ~70% of APA20,21. This signaling pathway plays an important role in the development 
of the adrenal cortex and in aldosterone biosynthesis22. Recent studies have suggested a two-hit mechanism of APA 
development, whereby a first hit induces adrenal cortex remodeling and/or increases nodule formation and a sec-
ond hit, involving mutations in APA driver genes, specifies the hormonal secretory pattern23,24.
In mice, the adrenal cortex is composed of two distinct functional zones, the zona glomerulosa (ZG) and the 
zona fasciculata (ZF), with different functions. The ZG is located under the capsule and produces mineralocorti-
coids that play a major role in the regulation of blood pressure by regulating sodium and potassium homeostasis. 
The ZF produces glucocorticoid hormones that are involved in stress response and energy homeostasis. Adrenal 
cortex undergoes continual renewal, with stem/progenitor cells that first differentiate into ZG cells and then 
migrate centripetally acquiring ZF cells characteristics25. Different studies report sexual dimorphism in mouse 
adrenal cortex, with adrenals being larger in females than in males and plasma ACTH, corticosterone and aldos-
terone levels being higher26. At the transcriptome level, a core sexually dimorphic expression program has been 
identified26. Moreover, sexual dimorphism in the adrenal cortex pathophysiology has been reported in several 
genetically modified mouse models21,27–29. Interestingly, adrenal cortex renewal has been recently shown to be 
3-fold faster in females than in males, highlighting the role of sex hormones in this process30.
Here we have performed a large-scale study integrating transcriptome, histological and immunohistological 
analyses with clinical and biological information of patients with APA to better understand the mechanisms 
involved in increased cell proliferation in BAH and APA development and to identify specific signaling pathways 
responsible for abnormal cell proliferation and nodule formation. We identified retinoic acid receptor (RAR) α 
signaling as a central molecular network involved in nodule formation. Analysis of the adrenal phenotype of mice 
lacking Rarα revealed structural and functional disorganization of the adrenal cortex at 12 weeks of age, which 
was associated with modifications of the extracellular matrix and vessel architecture in both male and female 
mice. This was accompanied by increased adrenal cortex weight in female, and increased cell proliferation in male 
mice. In males, morphological abnormalities were associated with alterations in non-canonical Wnt signaling as 
well as reduced expression of steroidogenic genes, without modifications in canonical Wnt signaling nor PKA 
signaling. Abnormalities of vessel architecture and extracellular matrix were due to decreased Vegfa expression 
and modifications in extracellular matrix components. With aging, adrenal cortex disorganization was still pres-
ent, but without evidence of modification of Wnt signaling and Vegfa or steroidogenic gene expression. In female 
Rarα−/− mice, morphological abnormalities of the adrenal cortex were also present at both ages. However, even at 
12 weeks, no alterations in Wnt signaling and Vegfa expression were observed, suggesting that molecular abnor-
malities may have occurred at an earlier time point in adrenal cortex development. Our study suggests that Rarα 
contributes to the maintenance of normal adrenal cortex structure and cell proliferation, by modulating Wnt 
signaling. Dysregulation of this interaction may contribute to abnormal cell proliferation, creating a propitious 
environment for the emergence of specific driver mutations in PA.
Results
Decrease of retinoic acid receptor α expression is associated with nodulation in APA. We com-
pared the transcriptome profile of 48 APA and 11 control adrenals. Unsupervised clustering revealed the presence 
of at least three different groups of samples (Fig. 1A). The first one being composed exclusively of control adrenals, 
whereas the 48 APA were subdivided into two groups of 43 and 5 samples defined as APA group A (APA_A) and 
APA group B (APA_B), respectively. The APA_B is spatially separated from the rest of the samples (Fig. 1B), and 
from this perspective control adrenals seem to be very similar to samples in APA_A. However, using the first 
three dimensions of a Principal Component Analysis (PCA), APA_A are clearly separated from control adrenals 
and from APA_B (Fig. 1C). By comparing clinical and biochemical characteristics of patients from APA_A and 
APA_B, we found no difference between groups except for the tumor size [15 mm (9–18) for APA_A versus 
40 mm (32–52.5) for APA_B (Table 1)]. Interestingly, another major difference characterizing these two groups 
of tumors was the level of expression of CYP11B2 (aldosterone synthase) detected by immunohistochemistry, 
sets to indicate the relative proportion of the overlapping regions to the corresponding list of candidate genes. 
Figures displayed are the number of genes that populate each of the selected sets. (F) Expression of RARα 
was investigated by RT-qPCR on mRNA extracted from 6 control adrenals and 19 APA. Values are presented 
as the mean ± SEM; p values were calculated using a two-sided Mann-Whitney test. *p < 0.05. (G) RARα 
immunohistochemistry performed on control adrenal and in APA.
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which was higher in APA_A compared to APA_B (Fig. 1D). The three groups were pairwise compared to obtain 
a list of statistically significantly differentially expressed genes for each of the three comparisons (Supplementary 
Tables 1–3). The common and comparison-specific genes were then classified into 7 different groups, some of 
which were associated to a specific biological process (Fig. 1E and Supplementary Fig. 1; Supplementary Tables 4–
10). In particular, we made the hypothesis that genes commonly differentially expressed in APA_A (high aldos-
terone production) and APA_B (low aldosterone production) compared to control adrenals would be involved 
in nodulation (Fig. 1E, subgroup 2) rather than steroid biosynthesis. Within this group, the expression of retinoic 
acid receptor α (RARα) was significantly down regulated in APA (logQ[APA_A vs CA] -3.8852; logQ[APA_B 
vs CA] -3.0056). RT-qPCR performed on 6 control adrenals and 19 APA confirmed the down-regulation of 
RARα mRNA expression in APA (Fig. 1F). Immunohistochemistry showed that RARα was expressed through-
out the adrenal cortex, and to a lesser extent in the medulla; its expression was heterogeneous in APA (Fig. 1G). 
Our transcriptome data also revealed that all the enzymes necessary for the biosynthesis of RA are expressed 
in control adrenal cortex as well as in APA (Table 2), supporting the possibility of RA biosynthesis and action 
in the adrenal gland. Modulation of RARα target genes was investigated by retrieving, from our transcriptome 
data, the expression of 511 genes described as RARα target genes and expressed in humans31 (Supplementary 
Table 11). Among them, 147 were found to be differentially expressed between APA_A and control adrenals (67 
were up-regulated and 80 down-regulated) and 123 between APA_B and control adrenals (10 up-regulated and 
113 down-regulated).
Significant disorganization of the adrenal cortex in 12 weeks old male and female Rarα−/− mice. 
To evaluate the role of Rarα in adrenal cortex structure and function, we compared the adrenal phenotype of 12 
weeks old male and female Rarα+/+ and Rarα-/- mice. As previously described32, the Rarα-/- mice exhibited 
growth retardation characterized by lower total body weight (Table 3). Relative adrenal weight of Rarα+/+ and 
Rarα-/- was similar in male mice, while it was significantly increased in female Rarα-/- mice (Table 3) com-
pared to wild type littermates. HES staining revealed marked disorganization of the adrenal cortex, character-
ized by a loss of the radial organization of the zona fasciculata (ZF) in both male and female mice (Fig. 2A and 
Supplementary Fig. 2), with a conserved zona glomerulosa (ZG). Confirming the HES observation, the expres-
sion of Disabled-2 (Dab-2), a marker of ZG33, was not affected in Rarα-/- mice (Fig. 2A,B), indicating that only 
the ZF was affected in both males and females. We also investigated the expression of 20-αHSD, a marker of the 
fetal X-zone34, which regresses at puberty in males and after the first gestation in females. No modification of 
20-αHSD expression was observed in Rarα-/- mice compared to wild type littermates, with the X-zone being 
visible in females but not in males in both genotypes (Supplementary Fig. 3), suggesting that the development and 
the regression of the fetal X-zone was unaffected. Total number of nuclei in adrenal cortex, indirectly reflecting 
adrenal cortex size, was significantly higher in 12 weeks old male and female Rarα-/- mice (Fig. 2C). In males, 
this was associated with an increased proliferation, highlighted by an increase of Ki67 positive nuclei in the adre-
nal cortex in Rarα-/- mice, (Fig. 2A,D). Although the proliferative index was not changed (Fig. 2A,D) in 12 weeks 
old female Rarα-/- mice, the adrenal weight was significantly increased (Table 3) in addition to ZF expansion, 
suggesting that increased proliferation may have occurred at an earlier time point during development.
Group A Group B P value
Gender (male/female), % 51/49 40/60 1
Age at PA dg (ys) 39 (33, 44.5) 43 (36.5, 51) 0.29
Lowest plasma K (mmol/l) 3.2 (2.9, 3.5) 3.1 (3.0, 3.55) 0.78
Systolic BP (mmHg) 150 (135, 167) 154 (143, 175) 0.49
Diastolic BP (mmHg) 90 (82, 99) 95 (85, 102) 0.56
Treatment score (n) 2 (1, 3.5) 1 (0, 2) 0.07
Urinary aldosterone (nmol/24 h) 95 (76, 126) 115 (87.5, 153.5) 0.57
Plasma aldosterone (pmol/l) 845 (508, 1127) 1168 (633.5, 1797) 0.32
Plasma renin (mU/l) 2.2 (1.4, 4.3) 1.7 (1.2, 3.4) 0.42
ARR (pmol/mU) 271.8 (179.8, 602.5) 831.0 (385.5, 1152) 0.16
Adenoma size (mm) 14.5 (9.0, 18.0) 40 (32.0, 52.5) <0.0001
Systolic BP at FU (mmHg) 131 (120, 149) 116 (112, 142) 0.31
Diastolic BP at FU (mmHg) 84 (80, 96) 73 (72, 94) 0.34
Treatment score at FU (n) 0 (0, 2) 0 (0, 2) 0.63
Plasma K at FU (mmol/l) 4.1 (3.8, 4.3) 4.0 (3.6, 4.2) 0.45
Plasma aldosterone at FU (pmol/l) 130 (85, 251) 74 (36, 200) 0.15
Plasma renin at FU (mU/l) 11.0 (6.8, 17.2) 9.0 (7.9, 101.3) 0.80
ARR at FU (pmol/mU) 14.1 (7.0, 17.8) 9.0 (7.9, 101.3) >0.99
Table 1. Clinical and biochemical correlates of patients from group A and B. PA: primary aldosteronism; HTN: 
hypertension; K: potassium; BP: blood pressure; ARR: aldosterone to renin ratio; FU: follow-up. Categorical 
data reported as number (percentage) and compared with Fischer’s exact test; quantitative data reported as 
median (interquartile range) and compared with the Mann-Whitney test (p significant if <0.05).
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Aldosterone synthase expression was found to be restricted to the ZG in both Rarα+/+ and Rarα-/- male and 
female mice (Fig. 3A). Interestingly, in both sexes, the localization of 11β-hydroxylase was not modified, despite 
ZF disorganization (Fig. 3A). However, the expression of genes coding for steroidogenic enzymes, including 
Star (Fig. 3B), Cyp11a1 (Fig. 3C), and Cyp11b1 (Fig. 3D) was reduced in 12 weeks male Rarα-/- mice, while the 
expression of Cyp11b2 was not significantly affected (Fig. 3E). Plasma aldosterone (Fig. 3F) and corticosterone 
levels (Fig. 3G), plasma renin concentration (Fig. 3H) and aldosterone to renin ratio (Fig. 3I) were not different 
in 12 weeks male Rarα-/- mice.
Modification of vessel architecture and extra cellular matrix composition in Rarα−/− mice. To 
gain mechanistic insight into the activity of Rarα in the adrenal cortex, microarray analysis was performed on 
adrenals from four Rarα+/+ and four Rarα-/- male mice. Hierarchical clustering allowed separating three out of 
four Rarα-/- mice from WT mice (Fig. 4A,B). Among the 243 statistically significantly differentially expressed 
genes, 184 genes (75.72%) were found to be upregulated and 59 (24.28%) down-regulated. Gene Ontology anal-
yses allowed the identification of specific molecular functions and biological processes enriched in 12 weeks 
Rarα+/+ versus Rarα-/- mice (Supplementary Fig. 2), which are mainly involved in specific metabolic processes, 
such as lipid, carboxylic acid or fatty acid metabolism. Interestingly, among the differentially regulated genes, 
Vegfa mRNA expression was found to be downregulated in Rarα-/- mice compared to Rarα+/+ mice (Fig. 4B, 
Supplementary Table 12). The down-regulation of Vegfa mRNA expression was confirmed by RT-qPCR in male 
mice only (Fig. 4C). The expressions of Vegfc, involved in angiogenesis and lymphangiogenesis, and of Hif1α, a 
marker of hypoxia, were unchanged (Fig. 4D,E). Sirius red staining, performed in male mice, revealed dilatation 
of vessels (Fig. 4F). In addition, podocalyxin staining of endothelial cells revealed disorganization of vessel archi-
tecture in both male and female Rarα-/- mice (Fig. 4F). Expression of fibronectin 1, microfibrillar associated 
protein 2 and 5 (Mfap2 and Mfap5) and of collagen 3α1, all components of the extracellular matrix (ECM), was 
found to be up-regulated in male Rarα-/- mice (Supplementary Table 12). To evaluate if Rarα inactivation alters 
ECM structure, laminin β1 staining was performed. Laminin β1, a component of the basement membrane of 
the ECM, was expressed homogeneously throughout the adrenal cortex in both male and female Rarα+/+ mice 
Gene name
Control 
adrenal APA p
Retinol Binding Protein 1 56.16 ± 7.30 81.77 ± 6.934 0.0673
Stimulated by Retinoic Acid 6 1.11 ± 0.13 1.485 ± 0.1561 0.3187
Retinol Dehydrogenase 5 1.05 ± 0.22 0.8240 ± 0.0730 0.2858
Retinol Dehydrogenase 11 19.30 ± 2.21 22.07 ± 1.466 0.2179
Retinol Dehydrogenase 12 (probe 2) 1.81 ± 0.35 5.704 ± 2.323 0.6776
Retinol Dehydrogenase 14 2.54 ± 0.32 3.914 ± 0.2692 0.0058
Aldehyde dehydrogenase 1 Family Member A1 24.28 ± 2.63 22.47 ± 2.589 0.3540
Aldehyde dehydrogenase 1 Family Member A3 2.72 ± 0.33 1.098 ± 0,1432 <0.0001
Cytochrome P450 Family 26 Subfamily B Member 1 1.69±0.37 0.8811 ± 0.1179 0.0189
Cellular Retinoic Acid Binding Protein 2 1.04 ± 0.31 1.076 ± 0.0825 0.2858
Table 2. Expression of enzymes responsible for retinoic acid biosynthesis in control adrenals (n = 11) and in 
APA (n = 48). Data are presented as mean ± SEM and are compared with the Mann-Whitney test or t-test (p 
significant if <0.05). Data are expressed as log2.
Male
12 weeks 52 weeks
Rarα+/+ Rarα−/− p Rarα+/+ Rarα−/− p
Total body weight (g) 28.12±0,59 26.45±0,70 0.0135 40.87±1.31 31.53±0.94 <0.0001
Left adrenal weight/total body weight (x1000) 1.531±0.112 1.678±0.144 0.7584 1.135±0.507 1.458±0.817 0.2736
Right adrenal weight/total body weight (x1000) 1.362±0.099 1.161±0.137 0.1112 1.173±0.684 1.460±0.687 0.1354
Left adrenal size (mm) N.D. N.D. 2.130±0.124 2.080±0.073 0.6663
Right adrenal size (mm) N.D. N.D. 2.015±0.068 2.069±0.066 0.7756
Female
Total body weight (g) 20.49±0.45 19.48±0.55 0.1612 29.97±1.75 23.25±0.71 0.0005
Left adrenal weight/total body weight (x1000) 2.044±0.091 2.474±0.188 0.0332 1.912±0.164 1.991±0.130 0.7108
Right adrenal weight/total body weight (x1000) 1.623±0.097 2.116±0.126 0.0036 1.506±0.105 1.784±0.162 0.1598
Left adrenal size (mm) N.D. N.D. 2.568±0.173 2.463±0.085 0.6095
Right adrenal size (mm) N.D. N.D. 2.430±0.156 2.260±0.132 0.3524
Table 3. Clinical characteristics of 12 and 52 weeks male and female Rarα+/+ and Rarα-/- mice. N.D.,  
Not Determined. Quantitative data reported as mean ± SEM and compared with the Mann-Whitney test  
(p significant if <0.05).
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(Fig. 4F). In Rarα-/- mice, expression of laminin β1 showed a gradient, with higher expression in the ZG than in 
the inner part of the ZF in male but not in female mice (Fig. 4F). Since expression of laminin β1 was not modified 
in microarray analyses, this suggests that modification of the expression of other components of the ECM may 
alter proper laminin β1 localization.
Inhibition of Wnt signaling in young Rarα−/− male mice. Wnt/β-catenin and PKA signaling are cen-
tral regulators of adrenal cortex development and function, with a fine equilibrium between the activation of 
Wnt/β-catenin pathway in the ZG and of PKA signaling in the ZF. To gain mechanistic insight into the changes 
responsible for structural modifications of the adrenal cortex in Rarα-/- mice, we thus explored Wnt/β-catenin 
signaling (Fig. 5). Whereas in female Rarα+/+ animals, β-catenin expression was restricted to the ZG with mem-
branous, cytoplasmic and nuclear localization, in male mice low expression was also detected in the external part 
Figure 2. Rarα affects adrenal cortex morphology in 12 weeks old male and female mice. (A) Morphological 
characterization of adrenals from 12 weeks old Rarα+/+ and Rarα-/- mice. HES staining, Dab-2 
immunofluorescence and Ki67 immunohistochemistry were performed on adrenal sections from the indicated 
group of mice. (B) Number of Dab-2 positive cells in the cortex was determined in 7 to 11 animals of each 
genotype and sex using an automated molecular imaging platform (Vectra, Perkin Elmer) and is expressed 
as a percentage of total number of cells in the entire cortex area. (C) Number of nuclei in the adrenal cortex 
was determined in 7 to 11 animals of each genotype and sex using an automated molecular imaging platform 
(Vectra, Perkin Elmer). (D) Relative proliferative index of adrenals from male and female Rarα+/+ and Rarα-/- 
mice. Ki67 positive cells were separately counted in the adrenal cortex in 5–6 animals per genotype and age. 
Values are presented as means ± SEM. *p<0.05; **p<0.01.
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of the ZF (Fig. 5A). In male Rarα-/- mice, high expression of β-catenin was observed in the outer layer of the 
adrenal cortex, extending into the ZF (Fig. 5A); the localization of β-catenin was unaffected in female Rarα-/- 
mice (Fig. 5A). Western blot performed on whole adrenals showed that the expression of β-catenin was not signif-
icantly increased in male and female Rarα-/- mice compared to wild type littermates (Fig. 5B,C), although a large 
variation of its expression was observed in male Rarα-/- mice (Fig. 5C) consistent with the extended localization 
observed in some animals. β-catenin phosphorylation is a marker of its activation state; phosphorylation on 
inactivating (T41/S45) (Fig. 5D) or activating (S552, S675) (Fig. 5E,F) residues was not affected by Rarα expres-
sion, indicating absence of activation of the canonical Wnt/β-catenin pathway in Rarα-/- mice. This was also 
supported by unchanged mRNA expression of Axin2 (Fig. 5J), a target gene of the canonical Wnt/β-catenin path-
way. In contrast, mRNA expression of Wnt4 (Fig. 5G), Tcf3 (Fig. 5H) and Lef1 (Fig. 5I), effectors and targets of 
non-canonical Wnt signaling, was reduced in adrenals from 12 weeks old Rarα-/- male mice. Modification of the 
expression of Wnt4 (Fig. 5G), a ligand involved in non-canonical Wnt signaling, of Frizzled-2, a transmembrane 
Figure 3. Impact of Rarα inactivation on adrenal steroidogenesis. (A) Expression of aldosterone synthase and 
11β-hydroxylase in 12 weeks old male and female Rarα+/+ and Rarα-/- mice. (B–F) Expression of steroidogenic 
genes in male and female Rarα+/+ and Rarα-/- mice. mRNA expression of Star (B), Cyp11a1 (C), Cyp11b1 (D) 
and Cyp11b2 (E) was assessed by RT-qPCR. RT-qPCR were performed on mRNA extracted from 6–11 adrenals 
from 12 weeks old male and female Rarα+/+ and Rarα-/- mice. (F,G) Measure of plasma aldosterone (F) and 
corticosterone (G) concentration by mass spectrometry in male mice. (H,I) Plasma renin concentration (PRC) 
(H) and aldosterone to renin ratio (I). Measure of plasma aldosterone, plasma corticosterone and plasma renin 
were done on 5–6 animals per group. Values are presented as the mean ± SEM; p values were calculated using a 
Mann-Whitney test or t-test. For correlation, Pearson calculations were performed. *p < 0.05; **p < 0.01.
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receptor of the non-canonical pathway (Supplementary Table 12) and of Tcf3 (Fig. 5H), a transcription factor that 
can act as a transcriptional repressor independently of β-catenin binding, suggests that the non-canonical Wnt 
signaling pathway is altered in Rarα-/- mice.
Figure 4. Rarα affects vessel architecture and extra cellular matrix composition. (A) Hierarchical clustering of 
samples using the 243 differentially expressed genes in adrenals from 12 weeks old Rarα+/+ and Rarα-/- male 
animals (4 animals per group). (B) Volcano plot showing the differentially expressed genes in 12 weeks old 
Rarα+/+ and Rarα-/- animals. The x-axis is the fold change between the two conditions; the adjusted p value 
based on –log10 is reported on the y-axis. Genes significantly different are highlighted as green (down-regulated 
in Rarα-/- mice) or red (up-regulated in Rarα-/- mice) dots. (C, D, E) The expression of genes involved in 
angiogenesis, Vegfa (C) and Vegfc (D) and in hypoxia, Hif1α (E) was investigated by RT-qPCR on mRNA 
extracted from 6–11 adrenals from 12 weeks old male and female Rarα+/+ and Rarα-/- mice. (F) The vascular 
architecture was assessed by Sirius red staining and podocalyxin immunofluorescence and extra cellular matrix 
integrity by laminin β1 immunofluorescence. Values are presented as the mean ± SEM; p values were calculated 
using a Mann-Whitney test. **p < 0.01.
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Since Rarα-/- mice show significant abnormalities of the ZF, we also explored protein kinase A (PKA) acti-
vation, which plays an important role in adrenal cortex development and function. It has been proposed that 
PKA prevents ZG differentiation through Wnt pathway inhibition, suggesting that PKA activation in the ZF is 
a key driver of Wnt inhibition35. PKA is the main kinase responsible for the phosphorylation of specific tran-
scription factors including the cAMP response element-binding protein (CREB)36. p-CREB was detected in the 
entire cortex in Rarα+/+ and Rarα-/- (Supplementary Fig. 4), where its expression was detected in >70% of 
the cells (Supplementary Fig. 4). Western blot analysis of CREB and p-CREB expression, performed on whole 
adrenals, revealed no change in total CREB expression or in its phosphorylation status depending on genotype 
(Supplementary Fig. 4). mRNA expression of Prkar1a and Prkaca, the genes coding for the regulatory and cata-
lytic subunit of PKA, was reduced in Rarα-/- animals (Supplementary Fig. 4); given the concomitant modifica-
tion of both subunits, this did not affect the expression of S100a4, a target gene of PKA activation in the adrenal37 
(Supplementary Fig. 4).
Significant disorganization of the adrenal cortex persists with aging. As Rarα was identified as 
associated with abnormal cell proliferation and nodule formation in APA, we evaluated the evolution of adrenal 
abnormalities with aging by investigating the adrenal phenotype of Rarα-/- animals at 52 weeks of age (Fig. 6 
and Supplementary Fig. 5). Growth retardation was more pronounced in 52 weeks old compared to 12 weeks 
Figure 5. Rarα inactivation alters Wnt signaling pathway in 12 weeks old male mice. (A) Expression of 
β-catenin was evaluated by immunofluorescence in 12 weeks old male and female Rarα+/+ and Rarα-/- mice. 
(B) Expression and phosphorylation of β-catenin in response to Rarα invalidation. Proteins were extracted 
from total adrenal and submitted to western blot analysis. Phosphorylation/dephosphorylation in activating 
(pS552 and pS675) and inactivating (pT41/S45) residues and total expression of β-catenin was investigated. (C–
F) Quantification of β-catenin expression (C) and of phospho-specific signals in inactivating (D) and activating 
(E,F) residues was performed in Rarα+/+ and Rarα-/- adrenal. (G-J) The expression of Wnt4 (G), Tcf3 (H), Lef1 
(I) and Axin2 (J) was investigated by RT-qPCR on mRNA extracted from 6 to 11 adrenals from Rarα+/+ and 
Rarα-/- male and female mice. Values are presented as mean ± SEM; p values were calculated using a Mann-
Whitney test or t-test. *p < 0.05; **p < 0.01.
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old mice, with smaller weight for both male and female Rarα-/- compared to Rarα+/+ mice; the relative adrenal 
weight was similar in both genotypes (Table 3). Adrenal morphology and size, evaluated by magnetic resonance 
imaging, was also similar in both genotypes and sexes (Table 3). Similar to 12 weeks old Rarα-/-, we observed 
loss of radial organization of the ZF with a conserved ZG in both male and female mice at 52 weeks of age 
(Fig. 6A,B), and absence of the fetal X-zone in both genotypes (Supplementary Fig. 3). However, at 52 weeks, the 
proliferation index and adrenal cortex size were similar in Rarα-/- mice compared to their wild type littermates 
(Fig. 6C,D). No differences were observed in the localization of aldosterone synthase or 11 β-hydroxylase expres-
sion (Fig. 6A). Unlike 12 weeks old animals, there was no difference in the expression of steroidogenic genes 
such as Star (Fig. 6E), Cyp11a1 (Fig. 6F), and Cyp11b2 (Fig. 6H) in Rarα-/- mice; a slightly decreased expression 
of Cyp11b1 (Fig. 6G) was observed in female mice only. Again, plasma aldosterone (Fig. 6I) and corticosterone 
(Fig. 6J) levels, plasma renin concentration (Fig. 6K) and aldosterone to renin ratio (Fig. 6L) were not different in 
Rarα-/- mice. However, 50% of male Rarα-/- mice showed high plasma aldosterone concentrations (up to 1000 
pmol/l), which were associated with higher plasma renin concentration (Fig. 6K).
Vessel dilatation (Sirius red) and disorganization (podocalyxin) as well as abnormal laminin β1 localization 
were still present in both male and female mice (Supplementary Fig. 5), but expression of Vegfa was not modified 
in Rarα-/- mice at 52 weeks of age (Supplementary Fig. 5). β-catenin was localized to the ZG (Supplementary 
Fig. 5), with an extended expression in ZF that could be observed in restricted areas in some animals (data not 
shown). Consistently with this observation, despite similar β-Catenin protein levels in Rarα+/+ and Rarα-/- 
mice (Supplementary Fig. 5), a large variation in its expression was observed (Supplementary Fig. 5). Again, 
β-Catenin phosphorylation on activating (pS552 and pS675, Supplementary Fig. 5) or inactivating (pT41/S45, 
Supplementary Fig. 5) residues were unchanged, indicating again that canonical Wnt/β-Catenin signaling was not 
modified in 52 weeks old Rarα-/- mice. In contrast to 12 weeks old Rarα-/- mice, only the expression of Lef1 was 
reduced in 52 weeks old male Rarα-/- mice (Supplementary Fig. 5), while the expression of Wnt4 (Supplementary 
Fig. 5), Tcf3 (Supplementary Fig. 5) and Axin 2 (Supplementary Fig. 5) was similar in both genotypes. Similar to 
12 weeks old mice, PKA signaling was unaltered at 52 weeks of age (Supplementary Fig. 4). However, p-CREB 
expression was reduced (<20% of cells, Supplementary Fig. 4) and found to be restricted to the external part of 
the adrenal cortex, mainly the ZG, in both Rarα+/+ and Rarα-/- animals at that age (Supplementary Fig. 4).
Microarray analysis performed on adrenals from four Rarα+/+ and four Rarα-/- 52 weeks old male mice 
revealed that 63 genes (60%) were upregulated and 42 (40%) down-regulated in Rarα-/- mice. Despite the low 
number of differentially regulated genes, hierarchical clustering allowed separating adrenals form Rarα+/+ and 
Rarα-/- mice (Supplementary Fig. 6). The expression of some genes involved in retinoic acid biosynthesis was 
found to be increased (alcohol dehydrogenease 1 and 7), possibly to compensate for the lack of Rarα expression 
(Supplementary Table 13). Furthermore, the expression of Mrap (Melanocortin 2 receptor accessory protein) was 
also found to be upregulated in these mice. Mrap has recently been shown to play a role in adrenal cortex zonation 
through the modulation of adrenal progenitor cell differentiation. Absence of Mrap was found to be associated 
to Wnt4/β-Catenin pathway dysregulation in ZG cells, showing an involvement of both the canonical and the 
non-canonical Wnt/β-Catenin pathway in adrenal gland zonation38.
Discussion
Several germline and somatic mutations cause excessive aldosterone production in PA. Although the functional 
link between those mutations and aldosterone production has been clearly established, the mechanisms leading 
to nodule formation appear to be complex and to partly involve different mechanisms39. Here we report the 
identification of RARα as being a key element in the regulation of adrenal cortex structure and cell prolifera-
tion. Inactivation of Rarα in mice led to significant structural disorganization of the adrenal cortex in male and 
female, with increased adrenal cortex size in female mice and increased cell proliferation in males, but no major 
modifications of aldosterone production. This disorganization is associated with modifications of the vessel archi-
tecture and ECM due to decreased Vegfa expression and modifications in ECM components. On the molecular 
level, Rarα inactivation leads to inhibition of the non-canonical Wnt signaling, without affecting the canonical 
Wnt Pathway nor PKA signaling. These molecular abnormalities were detected at 12 weeks in male mice only, 
suggesting that in female mice they may have occurred earlier in adrenal cortex development. At 52 weeks of age, 
the marked disorganization of the adrenal cortex persists in absence of molecular abnormalities in Wnt or Vegf 
signaling.
RAR belongs to the super-family of nuclear receptors; there are three subtypes of RAR: α (NR1B1), β (NR1B2) 
and γ (NR1B3). RAR functions as a ligand dependent transcription factor, which heterodimerizes with another 
receptor of the same family, the retinoic X receptor (RXR). RXR/RAR heterodimers bind to specific DNA 
sequences, the retinoic acid (RA) response element (RAREs) composed of two direct repeats of a core hexameric 
motif (A/G) G [G/T] TCA located in the regulatory regions of target genes40,41. In the absence of ligand, RARs 
are bound to RAREs in association with large protein complexes, which maintain chromatin in a condensed and 
repressed state42. Ligand binding is facilitated by association of RAR with cellular RA binding proteins. This bind-
ing induces conformational changes in the ligand-binding domain of the receptor, resulting in corepressor release 
and coordinated recruitment of a series of coregulator complexes.
RA mediated transcription plays critical roles in a variety of biological processes, including development, 
reproduction, immunity, organogenesis and homeostasis43. Moreover RARs are involved in cancer development, 
due to mutations, fusions to other proteins, altered expression or aberrant post-translational modifications. These 
alterations result in modified function and disruption of homeostasis, due to the capacity of RAR to regulate 
growth and differentiation. In human myeloid leukemia, the RARα gene is the target of chromosomal rearrange-
ments resulting in the production of fusion proteins that allow the cells to continue to proliferate and/or prevent 
the terminal differentiation seen in normal myelocytes44. Considering the associations between RAR and tumor-
igenesis, RAR are considered as tumor suppressor. In some cases, RAR have been correlated with survival instead 
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Figure 6. Adrenal cortex disorganization persists with aging in Rarα-/- mice. (A) Morphological 
characterization of adrenals from 52 weeks old male and female Rarα+/+ and Rarα-/- mice. HES staining, 
Dab-2, aldosterone synthase and 11β-hydroxylase immunofluorescence and Ki67 immunohistochemistry 
were performed. (B) Number of Dab-2 positive cells in the cortex was determined in 3 to 9 animals of each 
genotype and sex using an automated molecular imaging platform (Vectra, Perkin Elmer) and is expressed as 
a percentage of total number of cells in the entire cortex area. (C) Relative proliferative index of adrenals from 
male and female Rarα+/+ and Rarα-/- mice. Ki67 positive cells were separately counted in the adrenal cortex in 
5–6 animals per genotype. (D) Number of nuclei in the adrenal cortex was determined in 3 to 9 animals of each 
genotype and sex using an automated molecular imaging platform (Vectra, Perkin Elmer). (E–H) Expression 
of steroidogenic genes in male and female Rarα+/+ and Rarα-/- mice. mRNA expression of Star (E), Cyp11a1 
(F), Cyp11b1 (G) and Cyp11b2 (H) was assessed by RT-qPCR. RT-qPCR were performed on mRNA extracted 
from 6–8 adrenals from 52 weeks old male and female Rarα+/+ and Rarα-/- mice. (I,J) Measure of plasma 
1 2Scientific RepoRtS |         (2019) 9:14677  | https://doi.org/10.1038/s41598-019-50988-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
of growth arrest. Recently, proteomic characterization of adrenal gland embryonic development suggested a role 
of the retinoic acid receptor pathway in the early stages of adrenal gland development45. Moreover, transcriptome 
analysis identified LPS/IL-1 mediated inhibition of RXR function pathway in the top 5 canonical pathways asso-
ciated with genes differentially regulated in APA compared with adjacent ZG, suggesting a role of RXR pathways 
in APA46.
RA is a derivative of vitamin A (retinol), which is provided exclusively by diet. Vitamin A is converted into 
retinal by the action of alcohol dehydrogenases and short chain dehydrogenases/reductases. Then retinal is oxi-
dized into RA by retinaldehyde dehydrogenase47. In mice, the half-life of RA has been estimated to be about 
0.5 hours whereas retinol′s half-life is longer (3.6 hours)48, suggesting that RA could be produced locally in target 
tissues instead of being transported. All components of retinoic acid biosynthesis were identified in human and 
mouse adrenals in this study, supporting RA biosynthesis and action in the adrenal gland. Our data support a role 
for Rarα signaling in regulating cell proliferation: indeed, 12 weeks old male Rarα-/- mice show an increased 
proliferative index compared to wild type littermates. Despite no changes in proliferative index observed in 
female mice at 12 weeks of age, their adrenal weight was increased, suggesting that a proliferative phase may have 
occurred at earlier stages of adrenal development24.
The Wnt/β-catenin pathway is known to play an important role in embryonic development, stem cell main-
tenance, and differentiation in many tissues22,49–52. Depending on the Wnt-receptor complex formed, a β-catenin 
dependent (canonical pathway) or independent response (non-canonical pathway) is activated. In the canonical 
pathway, the binding of Wnt ligands (Wnt1, Wnt2, Wnt3a, Wnt8a, Wnt8b…) to specific frizzled – Low-density 
lipoprotein receptor-related protein (Lrp) complex leads to the dissociation of β-catenin from the degradation 
complex and its translocation into the nucleus where it induces the expression of specific target genes (Lef1, Axin 
2, c-jun, Cyclin D1, c-myc…)22 through binding to specific transcription factors (T-cell factor/lymphoid enhancer 
factor, Tcf/Lef). The Tcf/Lef family is composed of four members Tcf1, Lef1, Tcf3 and Tcf4. Whereas Tcf1 and 
Lef1 mediate transcriptional activation of Wnt target genes, Tcf3 acts as a transcriptional repressor, independently 
of β-catenin binding53. In addition to this canonical Wnt/β-catenin pathway, a non-canonical Wnt pathway has 
been described involving binding of other Wnt ligands (Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b and Wnt11) 
to frizzled receptors (Fzd2, Fzd3, Fzd4 and Fzd6), which signals through the c-Jun N-terminal kinase (JNK) and 
the Ca2+ signaling pathways22,54. Activation of the non-canonical pathway replaces Tcf1 by Tcf3 in the Tcf/Lef 
complex, changing the transcriptional program induced by Tcf/Lef binding to DNA55.
In the adrenal cortex, β-catenin expression is restricted to the ZG, suggesting a role for this pathway in the 
development of the adrenal cortex56. In Wnt4-deficient mice, a decrease in ZG cell number has been reported, 
resulting in a decrease of Cyp11b2 mRNA expression and aldosterone production. These mice also show ectopic 
expression of adrenal-like cells in the gonads, probably due to abnormal adrenocortical progenitor cell migration 
during development, suggesting a role for Wnt4 in cell sorting during development57. In our model, the expres-
sion of Wnt4 was highly correlated to the expression of Cyp11b2 in both male (r = 0.6015, p = 0.0064) and female 
(r = 0.5663, p = 0.0007) mice, supporting the role of Wnt4 in the regulation of Cyp11b2 expression. Similarly, the 
targeted disruption of β-catenin in steroidogenic Sf-1-expressing cells causes adrenal aplasia in newborn mice, 
further supporting a role for the Wnt/β-catenin pathway early in adrenal development56.
The marked disorganization of adrenal cortex structure observed in Rarα knockout mice, was associated to 
reduced expression of Lef1, Tcf3, Wnt4 and increased expression of Fzd2 (Supplementary Table 12), all involved 
in non-canonical Wnt signaling, in 12 weeks old Rarα-/- male mice. In contrast, β-catenin phosphorylation, 
which reflects the activation status of the canonical Wnt/β-catenin pathway, was unchanged. Interactions between 
the Wnt pathway and retinoic acid receptor signaling have been reported in some studies. Hence, in mouse 
embryonic stem cells, retinoic acid can concomitantly activate the non-canonical and inhibit the canonical Wnt 
pathway55. Similarly, the expression of Lef1, known to be regulated by the canonical Wnt pathway, can also be 
modulated by the non-canonical pathway58. In chondrocytes, retinoic acid, through RARα/RXRα activation, 
plays an important role in terminal differentiation through BMP2 and Wnt4 modulation59. More interestingly, 
retinoic acid has been proposed to inhibit β-catenin/Tcf activity downstream of β-catenin by inducing expres-
sion of secreted factors such as Wnt4 or Wnt1160. Increased expression of Tcf3, concomitantly with decreased 
expression of Tcf1 enhances the ability of Tcf3 to bind to specific Wnt response element, inducing changes in the 
transcriptional program of the cells55. Therefore, our results suggest that Rarα could contribute to the structural 
organization of the adrenal cortex through modification of the expression of Wnt4 and Tcf3, thus modulating the 
non-canonical Wnt pathway. Recently, downregulation of retinoic acid signaling (liver and retinoid X receptors 
LXR/RXR) was reported in adrenals of Siah1 KO mice. Siah1 KO mice exhibit severe disorganization of adrenal 
glands as well as increased aldosterone and corticosterone levels and vessel dilatation. Siah1 codes for an E3 
ubiquitin-protein ligase mediating ubiquitination and subsequent proteasomal degradation of target proteins, 
including PIAS1. On a molecular level, the stabilisation of PIAS1 leads to the enhancing sumoylation of Sf161 
and LXR62. Whereas, Sf1 sumoylation results in increased steroidogenesis, modification of retinoic acid signaling 
could contribute to adrenal cortex disorganization as well as vessel dilatation.
PKA signaling has been proposed to play a role in cell conversion from ZG to ZF and in maintenance of adre-
nal cortex zonation, acting through the modulation of the Wnt/β-catenin pathway, by inhibiting Wnt4 expres-
sion35. In 12 weeks old male Rarα-/- mice, the mRNA expression of both the regulatory and catalytic subunits 
of PKA (Prkar1a and Prkaca respectively) was downregulated; however CREB phosphorylation was not affected, 
aldosterone (I) and corticosterone (J) concentration by mass spectrometry in male mice. (K,L) Plasma renin 
concentration (PRC) and aldosterone to renin ratio. Measure of plasma aldosterone, plasma corticosterone and 
plasma renin were done on 5–6 animals per group. Values are presented as means ± SEM. *p < 0.05; **p < 0.01.
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neither was the expression of S100a4, a specific adrenal target gene of PKA37, suggesting that PKA activity was 
not affected. Therefore, the observed inhibition of the Wnt pathway does not appear to be due to modifications of 
PKA activity, but rather to a direct effect of Rarα.
Transcriptome analysis of adrenals from 12 and 52 weeks old Rarα+/+ and Rarα-/- mice, combined with 
specific staining revealed a decrease in Vegfa expression as well as abnormal vascular architecture. This was asso-
ciated with a differential pattern of expression of laminin β1, which was present in the entire adrenal cortex in 
Rarα+/+ mice, whereas a gradient of expression was observed in Rarα-/- mice with higher expression in the ZG 
than in the inner part of the ZF. The extracellular environment, in particular the vasculature and ECM, plays an 
important role in adrenal cortex structure and function, by modulating proliferation, migration, differentiation 
and survival of surrounding cells, but also steroidogenesis63,64. The ECM consists of the basement membrane 
and the interstitial ECM. The ECM is composed of polysaccharides and extracellular proteins such as collagens, 
laminins and fibronectin, but also some bioactive compounds (growth factors, enzymes, chemoattractants and 
morphogens), that form a three-dimensional network65. Laminins were found to be uniformly distributed in 
human adrenal cortex64,66; they have been proposed to play a role in adrenocortical cell migration through their 
chemotactic and haptotactic properties66. Interestingly, presence of RARα response elements has been identified 
in the laminin β1 promoter indicating regulation of its expression by retinoic acid67. Different studies reported 
that retinoic signaling participates in the regulation of the expression of ECM proteins as well as of cell mem-
brane ECM receptors in physiological and pathophysiological conditions68. The modification of expression of 
some components of the ECM such as Fibronectin 1, MFAP2, MFAP5 and of Collagen 3α1, associated to the 
modification of the pattern of expression of laminin β1 observed in the adrenal cortex of Rarα-/- mice strongly 
suggest a rearrangement of the ECM in absence of Rarα expression. These alterations of ECM composition could 
contribute to the disorganization of the adrenal cortex observed in our model, by modulating adrenocortical and 
vascular cell migration.
The adrenal gland is a highly vascularized tissue, each cell being in contact with at least one endothelial cell, 
allowing rapid release of hormones into the blood stream. Blood vessels present a centripetal pattern from super-
ficial arteries to the central vein69, following the radial organization of the adrenal cortex70. A characteristic fea-
ture of adrenal glands is the high expression of VEGF, which is produced by steroidogenic cells and is regulated 
by ACTH71. Interestingly, the Wnt pathway has also been involved in angiogenesis and vessel remodeling. It has 
been proposed that Wnt inhibition leads to vessel stability or regression whereas its activation could lead to angi-
ogenesis or vessel remodeling72,73. VEGF plays a central role to optimize vessel growth74; more importantly, many 
studies reported an effect of retinoic acid on VEGF expression; however depending on the cell models and the 
experimental conditions retinoic acid inhibits or stimulates VEGF expression75,76. Hence, the adrenal phenotype 
observed in Rarα-/- mice could be explained by a direct effect of deficient Rarα signaling on Vegfa signaling and 
Laminin β1 expression or by the inhibition of Wnt signaling, that could in turn also affect Vegf signaling. These 
modifications of the extracellular microenvironment in Rarα KO mice suggest that Rarα may affect the interplay 
between steroidogenic cell differentiation and migration, vasculature and extracellular matrix.
The development of specific mouse models in recent years has allowed a better understanding of the mech-
anism of male adrenal cortex development65,77; however little is still known in female mice. Sex differences in 
adrenal physiology have been demonstrated by Heitzmann and co-workers27. Invalidation of the Task1 potas-
sium channel leads to abnormalities of adrenal zonation and PA development, which occurs only in female mice 
after puberty. Testosterone treatment before puberty in female Task1-/- mice leads to normal adrenal zonation. 
Similarly, castration of male Task1-/- mice leads to abnormal zonation of the adrenal cortex similar to female 
Task1-/- mice. The comparison of gene expression profiles of male and female adrenals allowed the identification 
of a set of genes that are modulated according to sex and hormonal treatments26. These studies highlighted the 
critical role for sexual hormones in adrenal gland zonation and the existence of a sexual dimorphism. Comparison 
of the adrenal phenotype of male and female Rarα-/- mice revealed sex-specific molecular differences in young 
mice despite similar morphological abnormalities in adrenal gland development. This sexual dimorphism could 
be due to a different timing of the action of Rarα in adrenal development, with Rarα signaling occurring earlier in 
female than in male. As suggested by the adrenal phenotype of Task1-/- mice, sexual hormones, such as estrogen 
and androgens, may play a role in adrenal development and modulate the effect of Rarα inactivation.
In summary, our study identifies RARα as contributing to the maintenance of normal adrenal cortex structure 
and cell proliferation by modulating Wnt signaling. The absence of adrenal nodules in 52 weeks old mice suggests 
that abnormal cell proliferation induced by the absence of RARα signaling is not enough to promote APA, but 
may constitute one of the elements involved in the pathogenesis of PA. We propose a model in which a homeo-
static equilibrium between retinoic acid, Wnt and Vegf signaling pathways is required for the maintenance of nor-
mal adrenal cortex structure in a specific time-dependent manner that differs between males and females (Fig. 7). 
In addition to previously reported regulators and to further elements that remain to be identified, Ddysregulation 
of this equilibrium in adult adrenals may contribute to abnormal cell proliferation, creating the propitious envi-
ronment for the emergence of specific driver mutations in PA.
Methods
patients. Patients with primary aldosteronism were recruited between 2002 and 2006 through the COMETE 
(COrtico- et MEdullo-surrénale: les Tumeurs Endocrines) network (COMETE-HEGP protocol), approved by the 
French Research ethics committee (Comité de Protection des Personnes, CPP) under authorization number CPP 
2012-A00508-35. Methods for screening and subtype identification of PA were performed according to institu-
tional and Endocrine Society guidelines78,79. In patients diagnosed with primary aldosteronism, a thin slice CT 
scan or MRI of the adrenal and/or an adrenal venous sampling were performed to differentiate between unilateral 
and bilateral form. All patients gave written informed consent for genetic and clinical investigation.
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Microarray analysis on human tissues. Transcriptome analyses were performed on 48 APA samples 
and eleven control adrenals obtained from enlarged nephrectomies for renal carcinoma. Total RNA was iso-
lated from frozen tissue using Trizol (Invitrogen) and then cleaned-up on silica columns using RNeasy Mini Kit 
(Qiagen). The integrity and quality of the RNA were systematically checked using an Agilent 2100 Bioanalyzer 
with the RNA6000 Nano Assay (Agilent Technologies). For APA samples, complementary RNA was synthe-
sized from 15 μg of total RNA using the Chemiluminescent RT Labeling Kit (Applied Biosystems). For control 
adrenals, complementary cRNA was synthesized from 500 ng of total RNA using the NanoAmpTM RT-IVT 
Labeling Kit (Applied Biosystems). Samples were hybridized to microarrays using Applied Biosystems chemi-
luminescence detection kit according to the manufacturer’s protocol. Acquisition of the chemiluminescence 
images and primary data analysis were done using Applied Biosystems Expression Array System Software v1.1.1. 
Microarray gene expression data from the primary analysis for each sample was median centered, log 2 trans-
formed, model-adjusted, and quality controlled80. Mean expression profiles for each biological condition were 
obtained by variance-weighted averaging normalized expression values. Pairwised inter-array normalizations 
were carried out using the NeONORM method described previously81. Fold change values were expressed on log2 
scale. P-values were determined based on a normal distribution hypothesis of signal intensities using standard 
Figure 7. Proposed model for the role of Rarα in adrenocortical development. (A) Rarα regulates the 
expression of genes involved in the regulation of Wnt non-canonical pathway (Wnt4, Tcf3, Lef1…), angiogenesis 
(Vegfa) and Extra Cellular Matrix integrity (Fibronectin1, Collagen 3α1…) contributing to the organization 
of the adrenal cortex. Wnt4 activated pathway contributes to the differentiation of ZG cells, Vegfa to normal 
angiogenesis and Fibronectin1 and Collagen 3α1 being components of the Extra Cellular Matrix. (B) Model 
in which a homeostatic equilibrium between Rarα, Wnt and Vegf signaling pathways is required for the 
normal development of the vasculature and Extra Cellular Matrix structure, leading to normal adrenal cortex 
organization.
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methods82. Multiple probes for a single gene, cross-reactivity of a single probe to several genes, as well as the reso-
lution of probe-ID annotations were done as defined previously83. Hierarchical clustering based on Euclidean dis-
tance and complete-linkage was carried out using the R-packages hclust and gplot. Differentially expressed genes 
among groups were calculated using a fold-change z-test with positive false discovery rate correction. P values 
for over- and under-representation of pathways were calculated using a binominal distribution and a Bonferoni 
correction for multiple testing.
The data for the human APA transcriptome analysis have been deposited to the public data repository http://
mace.ihes.fr under accession nos.: 2575793518 (controls) and 2293267822 (APA).
Mice. Animal studies were conducted according to the guidelines and regulations formulated by the European 
Commission for experimental use (Directive 2010/63/EU) and were approved by the local Ethics committee of 
Paris Descartes University (N°17-020) and by the French Ministère de l′Enseignement Supérieur, de la Recherche 
et de l′Innovation (APAFIS authorization number #11509-201703281427107 v4). Rarα-/- mice (constitutive 
homozygous deletion of exon 8 of Rarα gene, leading to inactivation of the protein) have been kindly provided by 
Dr Norbert Ghyselinck and Dr Pierre Chambon32. They were maintained and bred on a mixed background and 
littermates control animals were used in all experiments. All experiments were conducted on male and female 
mice between 12 and 52 weeks of age. Blood were collected in abdominal aorta in lithium-heparin blood collec-
tion tubes (Microvette CB300LH, Sarstedt). The right adrenals were frozen in liquid nitrogen and the left adrenals 
fixed in 4% paraformaldehyde.
Magnetic resonance imaging. Anesthesia was induced with 4% isoflurane and maintained at a 1% level 
during imaging. Magnetic resonance imaging was performed with a dedicated small-animal 4.7 Tesla MR sys-
tem (Biospec 47/40 USR Brucker). The animals were placed in a supine position on a four-channel phased array 
receive coil inside a volume transmit coil (BruckerBiospin, Ettlingen, Germany). We performed two anatomic 
sequences (TurboRARA T2 and FISP) in two directions (coronal and sagittal) to optimized measurement of the 
size of the adrenal. The thickness of the slices was 0.7 mm and the resolution was 175×175 μm and 156×126 μm 
respectively.
Aldosterone, corticosterone and plasma renin concentration measurement in murine plasma 
samples. For steroids quantification, 150 μl of heparinized murine plasma was skiped with 500 ng of stable iso-
tope labeled internal standards for aldosterone and corticosterone. Following C18-based solid-phase-extraction, 
samples were subjected to LC-MS/MS analysis using a reversed-phase analytical column (Acquity UPLC® C18, 
Waters, Milford, MA, USA) operating in line with a XEVO TQ-S triple quadrupole mass spectrometer (Waters 
Xevo TQ/S, Milford, MA, USA) in multiple reaction monitoring mode. Internal standards were used to correct 
for analyte recovery across the sample preparation procedure in each sample. Analyte concentrations were cal-
culated from integrated chromatograms considering the corresponding responses determined in appropriate 
calibration curves in plasma matrix.
The plasma renin concentration was determined in murine plasma samples by determining the Ang I forma-
tion rate in the presence of excess of angiotensinogen, where it becomes solely dependent on the concentration of 
active renin. Therefore, diluted plasma was supplemented with an excess of recombinant murine angiotensino-
gen. Samples were incubated at 37°C in the presence of an Ang I stabilizing inhibitor cocktail for 60 minutes at 
37°C. Following LC-MS/MS based quantification of Ang I as described84, the Ang I formation rate was calculated 
by subtracting Ang I values obtained in non-incubated control samples and expressed in [(ng Ang I/ml)/h].
RNA extraction and RT-qPCR analysis. Total RNA was extracted using Janke and Kunkel’s Ultra-Turrax 
T25 (IKA technologies, Staufen DE) in Trizol reagent (Ambion Life Technologies, Carlsbad CA) according to 
the manufacturer’s recommendations. After deoxyribonuclease I treatment (Life Technologies, Calsbad CA), 
500 ng of total RNA were retro-transcribed (iScript reverse transcriptase, Biorad, Hercules, CA). The quantitative 
qPCR was performed using SYBRgreen (Sso advanced universal SyBr Green Supermix, Biorad, Hercules, CA) 
on a C1000 touch thermal cycler of Biorad (CFX96 Real Time System) according to the manufacturer’s instruc-
tions. Controls without template were included to verify that fluorescence was not overestimated from primer 
dimer formation or PCR contaminations. RT-qPCR products were analyzed in a post amplification fusion curve 
to ensure that a single amplicon was obtained. Normalization for RNA quantity and reverse transcriptase effi-
ciency was performed against three reference genes (geometric mean of the expression of Ribosomal 18S RNA, 
β2-microglobulin and Ubiquitin C for mouse samples and 18S RNA, GAPDH and HPRT for human samples), 
in accordance with the MIQE guidelines85. Quantification was performed using the standard curve method. 
Standard curves were generated using serial dilutions from a cDNA pool of all samples. The following primers were 
used: 5′-CCCTGCCCTTTGTACACACC-3′ and 5′-CGATCCGAGGGCCTCACTA-3′ for 18S; 5′-ATTCACCCC 
CACTGAGACTG-3′ and 5′-TGCTATTTCTTTCTGCGTGC-3′ for mβ2-microglobulin; 5′-AGCCCAGTGTTA 
CCACCAAG-3′ and 5′-ACCCAAGAACAAGCACAAG-3′ for mUbiquitinC; 5′-GTGCTTCATCCACTG 
GCTGGAA-3′ and 5′-GTCTGCGATAGGACCTGGTTGA-3′ for mStAR; 5′-TGCTCAACCTGCCTCCA 
GACTT-3′ and 5′-ACTGGCTGAAGTCTCGCTTCTG-3′ for mCyp11a1; 5′-TGTATCGAGAGCTGGCAGAG-3′ 
and 5′-CCTGGATGGCATCCATTGAC-3′  for mCyp11b1; 5′-ACCTACAGTGGCATTGTG-3′  and 
5′-GATTGCTGTCGTGTCAAC-3′ for mCyp11b2; 5′-CCCTGTCTTTGGGAAGGTGGTG-3′ and 5′-CACCTGC 
TGAAGAGATGGCGTATAC-3′ for mWnt4; 5′-CAGATGGTGGCCTGGATACT-3′ and 5′-CATCCCT 
GCTGTAGCTGTCA-3′  for mTcf3 ;  5′-AAATGGGTCCCTTTCTCCAC-3′  and 5′-TCGTCGCTG 
TAGGTGATGAG-3′ for mLef1; 5′-AGCCTAAAGGTCTTATGTGG-3′ and 5′-ATGGAATCGTCGGTCAGT-3′ for 
mAxin2; 5′-CCTGGTGGACATCTTCCAGGAGTACC-3′ and 5′-GAAGCTCATCTCTCCTATGTGCTGGC-3′ 
for mVegfa; 5′-GGGAAGAAGTTCCACCATCA-3′ and 5′-ATGTGGCCTTTTCCAATACG-3′ for mVegfc; 
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5′-TCAAGTCAGCAACGTGGAAG-3′ and 5′-TATCGAGGCTGTGTCGACTG-3′ for mHif1α; 5′-CGGGAATGC 
GAGCTCTATGT-3′ and 5′-CTCGAGTCAGTACGGATGCC-3′ for mPrkar1a; 5′-CCCGAGATTATCCT 
GAGCAA-3′ and 5′-ATAGGCTGGTCAGCGAAGAA-3′ for mPrkaca; 5′-TCCACAAATACTCAGGC 
AAAGAG-3′ and 5′-GCAGCTCCCTGGTCAGTAG-3′ for mS100a4; 5′-GTCTCCTCTGACTTCAACAGCG-3′ 
and 5′-ACCACCCTGTTGCTGTAGCCAA-3′ for hGAPDH; 5′-CTCAACTTTAACTGGAAAGAATGTC-3′ 
and 5′-TCCTTTTCACCAGCAAGCT-3′  for hHPRT ;  5′-GACCAGATCACCCTCCTCAA-3′  and 
5′-GTCCGAGAAGGTCATGGTGT-3′ for hRARα.
immunostainings. Immunohistochemistry and immunofluorescence were performed on Formalin-Fixed 
Paraffin-Embedded mouse adrenals from 12 and 52 week-old WT and KO male mice. Adrenal sections were dep-
araffinized in xylene and rehydrated through graded ethanol. To unmask the antigen, the slides were incubated in 
antigen unmasking solution (Vector laboratories Ltd) for 30 minutes at 98°C.
Immunofluorescence was performed for Dab2 (1/100, sc-13982, Santa Cruz Biotechnology), Laminin β1 
(1/500, ab69633, Abcam), β-catenin (1/1000, 61054, BD Transduction Laboratories), p-Creb (1/800, 9198, Cell 
Signaling Technology), mouse Cyp11b2 (mCyp11b2, 1/100, generous gift from CE Gomez-Sanchez), mouse 
Cyp11b1 (mCyp11b1, 1/50, generous gift from CE Gomez-Sanchez) and mouse podocalyxin (1/100, AF1556, 
R&D Systems). Tissues were permeabilized by a treatment of 15 min with TBS 0.1% Triton X100. The sections 
were then blocked with 5% BSA diluted in TBS for Dab2, laminin β1, β-catenin and p-Creb or with 10% normal 
donkey serum diluted in TBS 0.1% Triton X100 for mCyp11b2 and mCyp11b1. Primary antibodies were diluted 
in 3% BSA diluted in TBS (for Dab2, laminin β1, β-catenin and p-Creb) or in 5% normal donkey serum and 
10% normal rat serum diluted in TBS 0.1% Triton X100 (for mCyp11b2 and mCyp11b1) and incubated over-
night at 4°C (for laminin β1, β-catenin, p-Creb, mCyp11b2 and mCyp11b1) or 1 h at room temperature (Dab2). 
Primary antibodies were detected with donkey anti-rabbit Alexa 594 (1/400 for Dab2, laminin β1 and p-Creb, 
1/500 for mCyp11b2, A21207, Thermo Fisher), donkey anti-mouse Alexa 594 (1/400 for β-catenin, A21203, 
Thermo Fisher), Donkey anti-goat Alexa 594 (1/400 for mouse podocalyxin, A11058, Thermo Fisher) and 
Donkey anti-sheep Alexa 488 (1/500 for mCyp11b1, A11015, Thermo Fisher). Nuclei were conterstained using 
4′,6-diamidino-2-phenylindole (DAPI) (1/5000, Roche Diagnostics GmbH).
Immunohistochemistry was performed for mouse Ki67 (1/200, RM-9106, Thermo Fisher), mouse 20-αHSD 
(1/5000, generous gift from Y Weinstein), human RARα (1/500, ab28767, Abcam) and human CYP11B2 
(hCYP11B2, 1/100, generous gift from CE Gomez-Sanchez). Sections were incubated in 3% hydrogen peroxide 
(Sigma-Aldrich) for 10 min to inhibit endogenous peroxidases. Non-specific staining was blocked by incubating 
sections 30 min with 10% normal goat serum diluted in PBS for Ki67, 20-αHSD and RARα or 10% horse serum 
(HS) and 0.5% SDS diluted in Tris 0.1 M pH 7.4 for hCYP11B2. Primary antibodies were incubated overnight 
at 4°C: Ki67, 20-αHSD and RARα were diluted in 1% NGS or HS in PBS and CYP11B2 was diluted in 10% 
horse serum and 0.2% Tween 20 in Tris 0.1 M pH 7.4. Primary antibodies were detected by incubation for 30 min 
with affinity-purified goat anti-rabbit (1/400 for Ki67 and 20-αHSD; Vector Laboratories) or rabbit anti-goat 
(1/400 for RARα; Vector Laboratories) diluted in 1% normal goat serum in PBS or horse anti mouse (1/400 for 
hCYP11B2; Vector Laboratories) diluted in 10% horse serum and 0.2% Tween 20 in Tris 0.1 M pH 7.4. After 
incubation for 30 min with an avidin-biotin-peroxidase complex (Vectastain ABC Elite; Vector Laboratories), 
the slides were developed using diaminobenzidin (Vector Laboratories) and counter-stained using Hematoxylin 
Harris Heamatoxylin, RAL Diagnostics).
All microscopic examinations were done with a x10 and x20 objectives lens using Leica confocal or VectraTM 
system.
Multispectral images were acquired using a Vectra® automated imaging system and automatically quantified 
with InForm® software (both Perkin Elmer). Results of quantification are expressed in percentage of Dab2 or 
Ki67 positive cells over total adrenal cortex cells. Statistical significance was assessed among groups using t test 
or Mann-Whitney.
Histological examination. Histological examination was performed on 6 μm sections stained with 
hematoxylin-eosin safran (HES) and with Sirius red. Microscopic examinations were done with a x10 and x20 
objectives lens using VectraTM system or with a x40 objective lens using confocal SP8 Leica microscope.
Western blot. Western Blot analysis was performed on mouse adrenals from 12 and 52 week-old WT and 
KO male mice. Total proteins were extracted using RIPA buffer (RB 4475, BioBasic Canada) with EDTA-free 
protease and phosphatase inhibitor (Bimake), proteins were then spun on a rotor for 30 min and centrifuged 
at 13000 rpm for 15 min, the proteins were then recovered and concentration determined using Bradford pro-
tein essay (Biorad). 10 µg of total proteins were loaded on 10% Acrylamide SDS-PAGE gel, transferred onto 
nitrocellulose membrane and tagged with the following antibodies: phospho-β-Catenin (Thr41/Ser45; 1/1000, 
9565, Cell Signaling Technology), phospho-β-Catenin (Ser552; 1/1000, 5651, Cell Signaling Technology), 
phospho-β-Catenin (Ser675; 1/1000, 4176, Cell Signaling Technology), β-Catenin (1/1000, 8480, Cell Signaling 
Technology), phospho-CREB (Ser133; 1/1000, 9198, Cell Signaling Technology), CREB (1/1000, 9197, Cell 
Signaling Technology)anti-rabbit IgG, HRP-linked antibody (1/2000, 7074, Cell Signaling technology), 
β-actin (1/5000, 2228, Sigma-Aldrich) and anti-mouse IgG, HRP-linked antibody (1/5000, A90-146P, Bethyl 
Laboratories). The signals were developed by Clarity Max™ Western ECL substrate (Biorad, Hercules, CA) and 
detected by Fujifilm Las-4000 mini Luminescent image analyzer (Fujifilm, Tokyo-Japan) and quantified by Multi 
gauge software (Fujifilm, Tokyo-Japan). Expression of the phosphoprotein was normalized to the expression of 
the corresponding total protein and the expression of total proteins was normalized to the expression of the 
housekeeping protein β-actin.
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Microarray analysis of mouse adrenal gene expression. Adrenal gene expression profiles for 16 
mice (4 Rarα+/+ and 4 Rarα-/- 12 weeks old mice and 4 Rarα+/+ and 4 Rarα-/- 52 weeks old mice) were ana-
lyzed using Affymetrix Clariom S Mouse array. After validation of the RNA quality with Bioanalyzer 2100 (using 
Agilent RNA6000 nano chip kit), 100 ng of total RNA was reverse transcribed following the GeneChip® WT Plus 
Reagent Kit (Affymetrix). Briefly, the resulting double strand cDNA was used for in vitro transcription with T7 
RNA polymerase (all these steps are included in the WT cDNA synthesis and amplification kit of Affymetrix). 
After purification according to Affymetrix protocol, 5.5 μg of Sens Target DNA were fragmented and biotin labe-
led. After control of fragmentation using Bioanalyzer 2100, cDNA was then hybridized to GeneChip® Clariom S 
Mouse (Affymetrix) at 45°C for 17 hours. After overnight hybridization, chips were washed on the fluidic station 
FS450 following specific protocols (Affymetrix) and scanned using the GCS3000 7G. The scanned images were 
then analyzed with Expression Console software (Affymetrix) to obtain raw data (cel files) and metrix for Quality 
Controls.
Analyses were performed using TAC (Transcriptome Analysis Console) software. Genes with adjusted P value 
<0.05 and log2 fold changes <-1 or >1 were considered to be down- or up-regulated.
Molecular function and biological process enrichment analyses were performed using Gene Ontology (www.
geneontology.org). For the analyses, we used the list of differentially expressed genes in 12 or 52 weeks old 
Rarα+/+ and Rarα-/- mice. The analysis criteria were kept as default values. The data discussed in this publica-
tion have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accesion 
number GSE136801 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136801).
Statistics. Data are shown in mean ± SEM. Statistical significance was assessed between the groups using 
unpaired t-test or Mann-Whitney test (Prism, GraphPad Software, USA). A p-value <0.05 was considered sta-
tistically significant.
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